This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $794,849 to investigate mechanisms of cefiderocol resistance and cross-protection in Pseudomonas aeruginosa, a major cause of lung infections in cystic fibrosis patients. The key products and services delivered under this 5-year grant include:
-
Determining how specific gene mutations in Pseudomonas aeruginosa (such as CpxS) enable cross-protection against cefiderocol, a critical antibiotic, through increased siderophore production.
-
Elucidating the mechanisms by which the Pseudomonas siderophore pyochelin can sensitize the bacteria to cefiderocol killing.
-
Modeling and testing cefiderocol cycling strategies to reduce the development of resistance, leveraging the fitness costs associated with resistance mutations.
This research aims to optimize the use of cefiderocol and limit the emergence of resistant Pseudomonas strains, which can lead to longer hospital stays, higher healthcare costs, and increased mortality for cystic fibrosis patients. The grant was awarded to Cedars-Sinai Medical Center, a non-profit hospital and academic medical center in California.
Generated 3/25/25, 4:24 AM